These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32601956)

  • 1. Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China.
    Nie B; Guo Y; Zhang K; Liu J; Yun S
    Arch Virol; 2020 Sep; 165(9):2013-2020. PubMed ID: 32601956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
    Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
    Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.
    Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA
    Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.
    Di Maio VC; Cento V; Mirabelli C; Artese A; Costa G; Alcaro S; Perno CF; Ceccherini-Silberstein F
    Antimicrob Agents Chemother; 2014 May; 58(5):2781-97. PubMed ID: 24590484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.
    Kliemann DA; Tovo CV; da Veiga AB; de Mattos AA; Wood C
    World J Gastroenterol; 2016 Oct; 22(40):8910-8917. PubMed ID: 27833382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.
    Ahmed HR; Waly NGFM; Abd El-Baky RM; Yahia R; Hetta HF; Elsayed AM; Ibrahem RA
    PLoS One; 2021; 16(4):e0249770. PubMed ID: 33857212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women.
    Dryer PD; Limketkai BN; Martin CM; Ma G; Sherman KE; Taylor LE; Mayer KH; Jamieson DJ; Blackard JT
    J Antimicrob Chemother; 2009 Nov; 64(5):945-8. PubMed ID: 19767319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Naturally occurring NS5B variants resistant to non-nucleoside or nucleoside polymerase inhibitors among treatment-naïve hepatitis C patients in south China].
    Li Z; Liu Y; Cai Q; Shao X; Yan Y; Zhao Z
    Zhonghua Gan Zang Bing Za Zhi; 2015 Sep; 23(9):653-7. PubMed ID: 26524357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
    Young KC; Lindsay KL; Lee KJ; Liu WC; He JW; Milstein SL; Lai MM
    Hepatology; 2003 Oct; 38(4):869-78. PubMed ID: 14512874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patients.
    El-Tahan RR; Ghoneim AM; Zaghloul H
    Virus Genes; 2020 Oct; 56(5):564-581. PubMed ID: 32572756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6.
    Patiño-Galindo JÁ; Salvatierra K; González-Candelas F; López-Labrador FX
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2402-16. PubMed ID: 26856832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on different aspects of HCV variability: focus on NS5B polymerase.
    Marascio N; Torti C; Liberto M; Focà A
    BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S1. PubMed ID: 25234810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
    Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
    PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates.
    Jaspe RC; Sulbarán YF; Sulbarán MZ; Loureiro CL; Rangel HR; Pujol FH
    Virol J; 2012 Sep; 9():214. PubMed ID: 22995142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy.
    Sugihara K; Orito E; Tanaka Y; Kato T; Lau JY; Ohno T; Hayashi K; Ogino M; Hirashima N; Sakakibara K; Mizuno Y; Kato H; Suzuki S; Ueda R; Mizokami M
    Intervirology; 2006; 49(6):319-26. PubMed ID: 16926544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.
    Costantino A; Spada E; Equestre M; Bruni R; Tritarelli E; Coppola N; Sagnelli C; Sagnelli E; Ciccaglione AR
    Virol J; 2015 Nov; 12():186. PubMed ID: 26577836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.
    Sede MM; Laufer NL; Quarleri J
    Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity.
    Mejer N; Fahnøe U; Galli A; Ramirez S; Weiland O; Benfield T; Bukh J
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.